MAP4K4 and WT1 mediate SOX6‐induced cellular senescence by synergistically activating the ATF2–TGFβ2–Smad2/3 signaling pathway in cervical cancer
Molecular Oncology · 2024
DOI: 10.1002/1878-0261.13613 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, 2024. Verfasst von Han Zheng und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China. Hauptthemen laut MEDLINE: Activating Transcription Factor 2, Cellular Senescence, Signal Transduction, Smad2 Protein. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
SRY‐box transcription factor 6 ( SOX6 ) is a member of the SOX gene family and inhibits the proliferation of cervical cancer cells by inducing cell cycle arrest. However, the final cell fate and significance of these cell‐cycle‐arrested cervical cancer cells induced by SOX6 remains unclear. Here, we report that SOX6 inhibits the proliferation of cervical cancer cells by inducing cellular senescence, which is mainly mediated by promoting transforming growth factor beta 2 ( TGFB2 ) gene expression and subsequently activating the TGFβ2–Smad2/3–p53–p21 WAF1/CIP1 –Rb pathway. SOX6 promotes TGFB2 gene expression through the MAP4K4–MAPK (JNK/ERK/p38)–ATF2 and WT1–ATF2 pathways, which is dependent on its high‐mobility group (HMG) domain. In addition, the SOX6‐induced senescent cervical cancer cells are resistant to cisplatin treatment. ABT‐263 (navitoclax) and ABT‐199 (venetoclax), two classic senolytics, can specifically eliminate the SOX6‐induced senescent cervical cancer cells, and thus significantly improve the chemosensitivity of cisplatin‐resistant cervical cancer cells. This study uncovers that the MAP4K4/WT1–ATF2–TGFβ2 axis mediates SOX6‐induced cellular senescence, which is a promising therapeutic target in improving the chemosensitivity of cervical cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.
- NHC Key Laboratory of Medical Immunology, Peking University, Beijing, China.
- Department of Biomedical Informatics, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.
- Department of Radiation Oncology, Cancer Center of Peking University Third Hospital, Peking University Third Hospital, Beijing, China.
ORCID-Profile: Jie Wang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zheng, H., Liu, M., Shi, S., Huang, H., Yang, X., Luo, Z., Song, Y., Xu, Q., Li, T., Xue, L., Lu, F., & Wang, J. (2024). MAP4K4 and WT1 mediate SOX6‐induced cellular senescence by synergistically activating the ATF2–TGFβ2–Smad2/3 signaling pathway in cervical cancer. Molecular Oncology. https://doi.org/10.1002/1878-0261.13613
Vancouver
Zheng H, Liu M, Shi S, Huang H, Yang X, Luo Z, et al. MAP4K4 and WT1 mediate SOX6‐induced cellular senescence by synergistically activating the ATF2–TGFβ2–Smad2/3 signaling pathway in cervical cancer. Molecular Oncology. 2024. doi:10.1002/1878-0261.13613
BibTeX
@article{Zheng2024,
author = {Zheng, Han and Liu, Mingchen and Shi, Shu and Huang, Hongxin and Yang, Xingwen and Luo, Ziheng and Song, Yarong and Xu, Qiang and Li, Tingting and Xue, Lixiang and Lu, Fengmin and Wang, Jie},
title = {MAP4K4 and WT1 mediate SOX6‐induced cellular senescence by synergistically activating the ATF2–TGFβ2–Smad2/3 signaling pathway in cervical cancer},
journal = {Molecular Oncology},
year = {2024},
doi = {10.1002/1878-0261.13613}
}
EUVIMED